Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes

被引:31
作者
de Santiago, Ines [1 ]
Yau, Christopher [2 ]
Heij, Lara [3 ,4 ]
Middleton, Mark R. [5 ,6 ]
Markowetz, Florian [1 ]
Grabsch, Heike, I [3 ,7 ]
Dustin, Michael L. [8 ,9 ]
Sivakumar, Shivan [5 ,8 ]
机构
[1] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England
[2] Univ Birmingham, Ctr Computat Biol, Inst Canc & Genom Sci, Birmingham, W Midlands, England
[3] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Pathol, Med Ctr, Maastricht, Netherlands
[4] Univ Hosp RWTH Aachen, Dept Surg & Transplantat, Aachen, Germany
[5] Univ Oxford, Dept Oncol, Oxford, England
[6] Oxford Univ Hosp NHS Fdn Trust, OXford NIHR Biomed Res Ctr, Oxford, England
[7] Univ Leeds, Leeds Inst Med Res St Jamess, Div Pathol & Data Analyt, Leeds, W Yorkshire, England
[8] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England
[9] NYU, Sch Med, Dept Pathol, New York, NY USA
基金
英国医学研究理事会; 英国惠康基金;
关键词
pancreatic cancer; tumour microenvironment; T cells; adaptive immunity; innate immunity; subtypes; MUTATIONAL PROCESSES; METASTATIC MELANOMA; MOLECULAR SUBTYPES; ANALYSES REVEAL; CLASS DISCOVERY; PD-1; BLOCKADE; T-CELLS; TUMOR; SURVIVAL; INFILTRATION;
D O I
10.1002/ijc.32186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of the highest mortality rates of any cancer type with a 5-year survival rate of <5%. Recent studies of PDAC have provided several transcriptomic classifications based on separate analyses of individual patient cohorts. There is a need to provide a unified transcriptomic PDAC classification driven by therapeutically relevant biologic rationale to inform future treatment strategies. Here, we used an integrative meta-analysis of 353 patients from four different studies to derive a PDAC classification based on immunologic parameters. This consensus clustering approach indicated transcriptomic signatures based on immune infiltrate classified as adaptive, innate and immune-exclusion subtypes. This reveals the existence of microenvironmental interpatient heterogeneity within PDAC and could serve to drive novel therapeutic strategies in PDAC including immune modulation approaches to treating this disease.
引用
收藏
页码:1125 / 1137
页数:13
相关论文
共 50 条
  • [31] Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights
    Xu, Junyi
    Liu, Mingzhu
    Xue, Jing
    Lu, Ping
    CELLULAR ONCOLOGY, 2024, 47 (04) : 1475 - 1491
  • [32] Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
    Flaum, Nicola
    Hubner, Richard A.
    Valle, Juan W.
    Amir, Eitan
    McNamara, Mairead G.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 119 (07) : 932 - 940
  • [33] In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients
    Kurlinkus, B.
    Ahola, R.
    Zwart, E.
    Halimi, A.
    Yilmaz, B. S.
    Ceyhan, G. O.
    Laukkarinen, J.
    SCANDINAVIAN JOURNAL OF SURGERY, 2020, 109 (01) : 11 - 17
  • [34] Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis
    Frassini, Simone
    Calabretto, Francesca
    Granieri, Stefano
    Fugazzola, Paola
    Vigano, Jacopo
    Fazzini, Nicola
    Ansaloni, Luca
    Cobianchi, Lorenzo
    EJSO, 2022, 48 (09): : 1911 - 1921
  • [35] Proteomic analysis of pancreatic ductal adenocarcinoma
    Meleady, Paula
    Rahman, Rozana Abdul
    Henry, Michael
    Moriarty, Michael
    Clynes, Martin
    EXPERT REVIEW OF PROTEOMICS, 2020, 17 (06) : 453 - 467
  • [36] Histological variants of pancreatic ductal adenocarcinoma: a survival analysis
    Bengtsson, Axel
    Andersson, Roland
    Ansari, Daniel
    LANGENBECKS ARCHIVES OF SURGERY, 2024, 409 (01)
  • [37] Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
    Li, Ruiyu
    He, Yangzhige
    Zhang, Hui
    Wang, Jing
    Liu, Xiaoding
    Liu, Hangqi
    Wu, Huanwen
    Liang, Zhiyong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [38] Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management
    Ranasinha, Nithesh
    Omer, Altan
    Philippou, Yiannis
    Harriss, Eli
    Davies, Lucy
    Chow, Ken
    Chetta, Paolo M.
    Erickson, Andrew
    Rajakumar, Timothy
    Mills, Ian G.
    Bryant, Richard J.
    Hamdy, Freddie C.
    Murphy, Declan G.
    Loda, Massimo
    Hovens, Christopher M.
    Corcoran, Niall M.
    Verrill, Clare
    Lamb, Alastair D.
    BJUI COMPASS, 2021, 2 (01): : 13 - 23
  • [39] Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
    Sahin, I. H.
    Askan, G.
    Hu, Z. I.
    O'Reilly, E. M.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 2950 - 2961
  • [40] Models of pancreatic ductal adenocarcinoma
    Dennaoui, Rayane
    Shrestha, Hridaya
    Wagner, Kay-Uwe
    CANCER AND METASTASIS REVIEWS, 2021, 40 (03) : 803 - 818